Major bleeding · patients with unprovoked venous thromboembolism
VTE extended prophylaxis showed no clear difference in major bleedingd compared with another VTE extended prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortalitye · patients with unprovoked venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · patients with unprovoked venous thromboembolism
VTE extended prophylaxis showed no clear difference in clinically relevant non‐major bleedingf compared with another VTE extended prophylaxis (moderate certainty).
1 finding from 1 review
Strokeg · patients with unprovoked venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction · patients with unprovoked venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
VTE‐related mortality4 · patients with unprovoked venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent VTEb · patients with unprovoked venous thromboembolism
VTE extended prophylaxis probably leads to lower recurrent VTEb compared with another VTE extended prophylaxis (moderate certainty).
1 finding from 1 review
VTE‐related mortality4 · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in VTE‐related mortalitya compared with placebo (low certainty).
1 finding from 1 review
Recurrent VTEc · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in recurrent VTEc compared with placebo (moderate certainty).
1 finding from 1 review
Major bleedinge · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in major bleedinge compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortalityg · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in all‐cause mortalityg compared with placebo (moderate certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in clinically relevant non‐major bleedingh compared with placebo (low certainty).
1 finding from 1 review
Strokei · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in strokei compared with placebo (low certainty).
1 finding from 1 review
Myocardial infarction · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in myocardial infarction compared with placebo (low certainty).
1 finding from 1 review
HIV transmission at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth · Breastfeeding infants of HIV‐infected mothers
An extended NVP regimen administered to infants for 28 weeks may leads to lower HIV transmission at 28 weeks among those whose diagnostic testing… compared with 1 week of antiretroviral prophylaxis (low certainty).
1 finding from 1 review
Infant mortality at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth · Breastfeeding infants of HIV‐infected mothers
An extended NVP regimen administered to infants for 28 weeks showed no clear difference in infant mortality at 28 weeks among those whose diagnostic testing… compared with 1 week of antiretroviral prophylaxis (low certainty).
1 finding from 1 review
HIV transmission or death at 28 weeks among those whose diagnostic test was negative at 2 weeks · Breastfeeding infants of HIV‐infected mothers
An extended NVP regimen administered to infants for 28 weeks probably leads to lower HIV transmission or death at 28 weeks among those whose diagnostic… compared with 1 week of antiretroviral prophylaxis (moderate certainty).
1 finding from 1 review
Infants with Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers
An extended NVP regimen administered to infants for 28 weeks showed no clear difference in infants with Severe Adverse Events compared with 1 week of antiretroviral prophylaxis (low certainty).
1 finding from 1 review
HIV transmission at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth · HIV‐infected mothers and their breastfeeding infants
An extended antiretroviral regimen administered to mothers for 28… probably leads to lower HIV transmission at 28 weeks among those whose diagnostic testing… compared with 1 week of antiretroviral prophylaxis (moderate certainty).
1 finding from 1 review
Infant mortality at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth · HIV‐infected mothers and their breastfeeding infants
An extended antiretroviral regimen administered to mothers for 28… showed no clear difference in infant mortality at 28 weeks among those whose diagnostic testing… compared with 1 week of antiretroviral prophylaxis (low certainty).
1 finding from 1 review